Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

作者信息

Călugăru Dan, Călugăru Mihai

机构信息

Department of Ophthalmology, University of Medicine Cluj-Napoca, Cluj-Napoca, Romania.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1353-1354. doi: 10.1007/s00417-018-3951-7. Epub 2018 Mar 9.

DOI:10.1007/s00417-018-3951-7

PMID:29523991

Abstract

摘要

相似文献

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1353-1354. doi: 10.1007/s00417-018-3951-7. Epub 2018 Mar 9.

Reply to the letter to the editor: Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1355-1356. doi: 10.1007/s00417-018-3952-6. Epub 2018 Mar 10.

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):83-89. doi: 10.1007/s00417-017-3836-1. Epub 2017 Oct 29.

Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1133-1140. doi: 10.1007/s00417-017-3624-y. Epub 2017 Feb 25.

Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.

Am J Ophthalmol. 2016 Aug;168:290-291. doi: 10.1016/j.ajo.2016.05.015. Epub 2016 Jun 4.

Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.

Asia Pac J Ophthalmol (Phila). 2017 May-Jun;6(3):250-255. doi: 10.22608/APO.2016186. Epub 2017 Apr 10.

CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.

Retina. 2018 Sep;38(9):1801-1808. doi: 10.1097/IAE.0000000000002004.

Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.

JAMA Ophthalmol. 2016 Jan;134(1):95-9. doi: 10.1001/jamaophthalmol.2015.4110.

Letter to the Editor: Aflibercept For Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab And/Or Bevacizumab May Further Improve Macular Thickness.

Ophthalmic Surg Lasers Imaging Retina. 2017 Jul 1;48(7):528-529. doi: 10.3928/23258160-20170630-01.

Letter to the Editor: Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.

Ophthalmic Surg Lasers Imaging Retina. 2017 Apr 1;48(4):280. doi: 10.3928/23258160-20170329-01.

引用本文的文献

Romanian ophthalmologists in the renowned ophthalmic journals worldwide.

Rom J Ophthalmol. 2018 Oct-Dec;62(4):260-269.

Comment on "Intravitreal dexamethasone implants for diabetic macular edema".

Int J Ophthalmol. 2018 Dec 18;11(12):2029-2032. doi: 10.18240/ijo.2018.12.27. eCollection 2018.

Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema.

Graefes Arch Clin Exp Ophthalmol. 2019 Jan;257(1):241-242. doi: 10.1007/s00417-018-4126-2. Epub 2018 Sep 5.

本文引用的文献

Early Response to Intravitreal Dexamethasone Implant Therapy in Diabetic Macular Edema May Predict Visual Outcome.

Am J Ophthalmol. 2018 Feb;186:164-165. doi: 10.1016/j.ajo.2017.10.035. Epub 2017 Dec 6.

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):83-89. doi: 10.1007/s00417-017-3836-1. Epub 2017 Oct 29.

Letter to the Editor: Aflibercept For Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab And/Or Bevacizumab May Further Improve Macular Thickness.

Ophthalmic Surg Lasers Imaging Retina. 2017 Jul 1;48(7):528-529. doi: 10.3928/23258160-20170630-01.

Letter to the Editor: Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.

Ophthalmic Surg Lasers Imaging Retina. 2017 Apr 1;48(4):280. doi: 10.3928/23258160-20170329-01.

Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1451-1452. doi: 10.1007/s00417-017-3669-y. Epub 2017 Apr 7.

Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting.

Am J Ophthalmol. 2017 Feb;174:175-176. doi: 10.1016/j.ajo.2016.10.013. Epub 2016 Nov 25.

Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.

Am J Ophthalmol. 2016 Aug;168:290-291. doi: 10.1016/j.ajo.2016.05.015. Epub 2016 Jun 4.

TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.

Retina. 2015 Aug;35(8):1489-506. doi: 10.1097/IAE.0000000000000627.

Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

J Ocul Pharmacol Ther. 2015 Mar;31(2):78-86. doi: 10.1089/jop.2014.0037. Epub 2014 Oct 14.

Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis).

Am J Ophthalmol. 2009 Aug;148(2):266-71. doi: 10.1016/j.ajo.2009.03.006. Epub 2009 May 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr
超能文献

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献

Suppr超能文献

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献

Suppr
超能文献